These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
559 related articles for article (PubMed ID: 26414147)
1. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis. Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM; Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147 [TBL] [Abstract][Full Text] [Related]
2. Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. Castle PE; Wheeler CM; Campos NG; Sy S; Burger EA; Kim JJ; Prev Med; 2018 Jun; 111():177-179. PubMed ID: 29548787 [TBL] [Abstract][Full Text] [Related]
3. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus. Kim JJ; Burger EA; Sy S; Campos NG J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Kim JJ; Ortendahl J; Goldie SJ Ann Intern Med; 2009 Oct; 151(8):538-45. PubMed ID: 19841455 [TBL] [Abstract][Full Text] [Related]
5. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines. Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156 [TBL] [Abstract][Full Text] [Related]
6. The value of improving failures within a cervical cancer screening program: an example from Norway. Burger EA; Kim JJ Int J Cancer; 2014 Oct; 135(8):1931-9. PubMed ID: 24615416 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. van Rosmalen J; de Kok IM; van Ballegooijen M BJOG; 2012 May; 119(6):699-709. PubMed ID: 22251259 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua. Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477 [TBL] [Abstract][Full Text] [Related]
10. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381 [TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Holmes J; Hemmett L; Garfield S Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286 [TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Munshi VN; Perkins RB; Sy S; Kim JJ Am J Obstet Gynecol; 2022 Feb; 226(2):228.e1-228.e9. PubMed ID: 34547295 [TBL] [Abstract][Full Text] [Related]
14. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program. Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870 [TBL] [Abstract][Full Text] [Related]
15. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis. Yamamoto N; Mori R; Jacklin P; Osuga Y; Kawana K; Shibuya K; Taketani Y BJOG; 2012 Jan; 119(2):177-86. PubMed ID: 21794070 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299 [TBL] [Abstract][Full Text] [Related]
17. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Demarteau N; Van Kriekinge G; Simon P Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study. Jansen E; Naber SK; Aitken CA; de Koning HJ; van Ballegooijen M; de Kok I BJOG; 2021 Feb; 128(3):573-582. PubMed ID: 32638462 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon. Sharma M; Seoud M; Kim JJ Vaccine; 2017 Jan; 35(4):564-569. PubMed ID: 28017434 [TBL] [Abstract][Full Text] [Related]
20. Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing. Pedersen K; Burger EA; Sy S; Kristiansen IS; Kim JJ Gynecol Oncol; 2016 Nov; 143(2):326-333. PubMed ID: 27542966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]